KOREA WHO

Ahn Jae-yong is the CEO and president of SK bioscience.

He is focusing his capabilities on securing new growth engines as sales related to COVID-19 vaccines decline.

To prepare for the “next pandemic,” he is seeking to enter new fields such as messenger ribonucleic acid (mRNA) vaccines and cell and gene therapies.

He was born on November 14, 1967, in Seoul.

He graduated from Yeouido High School in Seoul and Yonsei University with a degree in economics, and completed a Master of Business Administration (MBA) program at the University of Chicago Booth School of Business in the United States.

He worked at Korea Export Insurance Corporation before moving to SK Chemicals.

At SK Chemicals, he served as head of the strategy team and head of the strategic planning office, and later led the vaccine business division, where he spearheaded the launch of “SKYCellflu Quadrivalent,” the world’s first quadrivalent cell-culture flu vaccine.

When SK Chemicals’ vaccine business division was spun off as SK bioscience, he was appointed CEO and was promoted to president.

He values collaboration with overseas organizations for the growth of the vaccine business. He believes that for a company to grow, it must create an environment where its members can do their jobs properly.

#AhnJae-yong #SKbioscience #SKChemicals #vaccine #COVID19vaccine #mRNAvaccine #cellandgenetherapy #SKYCellflu #biopharmaceuticals #nextpandemic